⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2586775 | 0.80 | ALDH1A1 (0.45) | — | |
| SCHEMBL28456854 | 0.80 | L3MBTL1 (0.42) | — | |
| SCHEMBL2348177 | 0.76 | KDM4E (0.42) | — | |
| SCHEMBL3602693 | 0.73 | ALDH1A1 (0.34) | — | |
| SCHEMBL485398 | 0.73 | — | — | |
| SCHEMBL11240410 | 0.73 | ALDH1A1 (0.38) | — | |
| SCHEMBL11736461 | 0.73 | DDB1 (0.37) | — | |
| SCHEMBL24137133 | 0.71 | — | — | |
| SCHEMBL18808390 | 0.71 | — | — | |
| SCHEMBL19231242 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119604487-A | Novel sulfimide derivative or pharmaceutically acceptable salt thereof and application thereof | 韩国科学技术研究院 | 2025-03-11 | — | — | CN | disclosed |
| WO-2023234759-A1 | NOVEL SULFANONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | 한국과학기술연구원 | 2023-12-07 | — | — | WO | disclosed |
| EP-3774755-B1 | SPIROCYCLIC COMPOUNDS AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | PHENEX DISCOVERY VERWALTUNGS GMBH (DE) | 2022-05-18 | — | — | EP | disclosed |
| US-9796723-B2 | Method of treatment using substituted imidazo[1,2b]pyridazine compounds | ARRAY BIOPHARMA, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170114068-A1 | Method of Treatment Using Substituted Imidazo[1,2b]Pyridazine Compounds | ARRAY BIOPHARMA, INC. | 2017-04-27 | — | — | US | disclosed |
| US-7666869-B2 | to provide an aliphatic nitrogen-containing 5-membered ring compound represented by the formula [I]:** Image-1wherein symbols in the formula have the following meanings;A: CH2 or S , antidiabetic agents | MITSUBISHI TANABE PHARMA CORP. (JP) | 2010-02-23 | — | — | US | disclosed |
| US-7666869-B2 | to provide an aliphatic nitrogen-containing 5-membered ring compound represented by the formula [I]:** Image-1wherein symbols in the formula have the following meanings;A: CH2 or S , antidiabetic agents | MITSUBISHI TANABE PHARMA CORP. (JP) | 2010-02-23 | — | — | US | disclosed |
| WO-2008157273-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080153821-A1 | Nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. | 2008-06-26 | — | — | US | disclosed |
| US-20080153821-A1 | Nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. | 2008-06-26 | — | — | US | disclosed |
| US-7332487-B2 | Nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. (JP) | 2008-02-19 | — | — | US | disclosed |
| US-7332487-B2 | Nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. (JP) | 2008-02-19 | — | — | US | disclosed |